Close Menu

NEW YORK -- OpGen announced after the close of the market on Tuesday an 8 percent revenue increase for the fourth quarter of 2019.

For the three months ended Dec. 31, 2019, OpGen's revenues grew to $821,674 from $758,959 million in Q4 2018. The company logged $570,674 in product revenue in Q4, and $250,000 in collaboration revenue.

Fourth quarter R&D expenses fell 42 percent to $1.1 million from $1.9 million, while SG&A costs dropped 19 percent to $1.7 million from $2.1 million.

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Don't have a GenomeWeb or 360Dx account?
Register for Free.

AstraZeneca has released its coronavirus vaccine trial protocol, according to the New York Times.

Time magazine looks into how liquid biopsies are changing cancer care.

According to the Guardian, more than 150 countries have signed on to a global SARS-CoV-2 vaccine plan.

In PNAS this week: similar muscle protein patterns across hypertrophic cardiomyopathy phenotypes, analysis of gene expression and brain anatomy in major depression, and more.